News & Updates

A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Potential drug-drug interactions (DDIs) exist in breast cancer patients undergoing cyclin-dependent kinase (CDK) 4/6 inhibitors chemotherapy, suggests a study.

A phase II study of patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL) reports decade-long remissions in approximately one-third of patients with large B-cell lymphomas (LBCL) and in nearly half of patients with follicular lymphoma (FL), following a single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel.